Posts

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics-induced CD8 T cell responses and clinical activity

on

REGENXBIO's Hunter Syndrome Gene Therapy RGX-121 Rejected by FDA

on

FDA Issues Draft Guidance on MRD and CR Endpoints for Accelerated Multiple Myeloma Drug Approvals

on

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

on

FDA Rejects Biohaven's Ataxia Drug Vyglxia, Forcing Company to Cut Costs After Second Approval Failure

on

Equillium's pivotal GvHD study of anti-CD6 antibody comes up short

on